PRACA ORYGINALNA
AUTOIMMUNOLOGICZNA CUKRZYCA DOROSŁYCH (LADA) – OPIS PRZYPADKU
 
Więcej
Ukryj
1
Z Katedry i Kliniki Chorób Wewnętrznych Uniwersytetu Medycznego w Lublinie
 
Med Og. 2009;15(4):585–590
SŁOWA KLUCZOWE
STRESZCZENIE ARTYKUŁU
W artykule przedstawiono przypadek 50-letniego mężczyzny z autoimmunologiczną cukrzycą dorosłych uznawaną początkowo za cukrzycę typu 2. Obraz kliniczny oraz słaba reakcja na doustne leki hipoglikemizujące po upływie 6 miesięcy od rozpoznania cukrzycy nasunęły podejrzenie cukrzycy typu LADA.

Diabetes seldom causes significant diagnostic problems. The report presents a case of 50-year-old male with LADA diabetes (latent autoimmune diabetes in adults). In this case, late onset of diabetes and increased patient’s body weight were the cause of primary diagnosis of type 2 diabetes and treatment with oral antidiabetic drugs. Poor effectiveness of these drugs 6 months after diagnosis of diabetes, as well as the presence of autoimmune diseases in family members, were the reason to perform further diagnostic tests. Low concentration of C peptide and the presence of serum glutamic acid decarboxylase antibodies confirmed the diagnosis of LADA. The implementation of insulin therapy helped to restore and maintain normoglycaemia.
 
REFERENCJE (9)
1.
Groop LC, Bottazzo GF, Doniac D. Islet cell antibodies identify latent type 1 diabetes in patients aged 35–75 years at diagnosis. Diabetes 1986; 35, 237-241.
 
2.
Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC.: Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005, 48, 2206-2012.
 
3.
P. Myhill, W. A. Davis, D. G. Bruce, I. R. Mackay, P. Zimmet and T. M. E. Davis: Chronic complications and mortality in community-based patients with latent autoimmune diabetes in adults: the Fremantle Diabetes Study. Diabetic Medicine 2008, 25, 1245-1250.
 
4.
Pozzilli P, Di Mario U.: Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 2001, 24, 1460-1467.
 
5.
Stenström G., Gottsäter A., Bakhtadze E., Berger B., Sundkvist G.: Latent autoimmune diabetes in adults, definition, prevalence, β-Cell function, and treatment. Diabetes 2005, 54, suppl.2, 68-72.
 
6.
Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnstrom BO, Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR, Groop LC: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999, 48, 150-157.
 
7.
Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR.: Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993, 42, 359-362.
 
8.
Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet. 1997, 350, 1288-1293.
 
9.
Wroblewski M, Gottsater A, Lindgarde F, Fernlund P, Sundkvist G.: Gender, autoantibodies, and obesity in newly diagnosed diabetic patients aged 40-75 years. Diabetes Care 1998, 21, 250-255.
 
eISSN:2084-4905
ISSN:2083-4543